Skip to main
RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast & Price Target

Reviva Pharmaceuticals (RVPH) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Reviva Pharmaceuticals Holdings Inc. showcases a promising outlook due to the demonstrated efficacy and safety profile of its lead drug candidate, Brilaroxazine, which has shown robust treatment benefits for schizophrenia across multiple phases of clinical trials. The ongoing Phase III RECOVER trial, alongside the encouraging long-term efficacy and tolerability data from the open-label study, supports the potential for sustained treatment benefits, marked by significant reductions in PANSS scores. Additionally, the company's unique chemical genomics-driven technology platform enhances its capacity for innovative drug development, positioning it favorably in the competitive pharmaceutical landscape.

Bears say

Reviva Pharmaceuticals Holdings Inc faces significant risks that undermine its market outlook, particularly regarding the pivotal development and approval of its lead candidate, Brilaroxazine. The company may experience downward valuation revisions due to potential issues with key patents, leading to inadequate market protection and commercial viability. Furthermore, Reviva's financial position is precarious, requiring further capital raises that may lead to shareholder dilution, while the uncertainty surrounding market adoption and commercial partnerships for Brilaroxazine adds to the negative sentiment.

Reviva Pharmaceuticals (RVPH) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Reviva Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Reviva Pharmaceuticals (RVPH) Forecast

Analysts have given Reviva Pharmaceuticals (RVPH) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Reviva Pharmaceuticals (RVPH) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Reviva Pharmaceuticals (RVPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.